LENZ Therapeutics, Inc. Common Stock (LENZ) is a publicly traded Healthcare sector company. As of July 6, 2026, LENZ trades at $5.52 with a market cap of $184.68M and a P/E ratio of -2.07. LENZ moved -5.86% today. Year to date, LENZ is -63.46%; over the trailing twelve months it is -80.98%. Its 52-week range spans $5.23 to $50.40. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces LENZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LENZ Launches Telehealth Prescribing and TV Campaign to Reach 128 Million Presbyopes: LENZ Therapeutics has made VIZZ available through a telehealth platform offering online evaluation by licensed eye care professionals plus prescription fulfillment and home delivery. The launch will be backed by a national TV advertising campaign featuring Sarah Jessica Parker to reach roughly 128 million Americans with presbyopia and boost adoption.
| Metric | Value |
|---|---|
| Price | $5.52 |
| Market Cap | $184.68M |
| P/E Ratio | -2.07 |
| EPS | $-2.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.40 |
| 52-Week Low | $5.23 |
| Volume | 586.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $19.09M |
| Net Income | $-82.13M |
| Gross Margin | 97.81% |
6 analysts cover LENZ: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.